In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Peter Lucas, M.D., Ph.D., vice chair of Research for the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic.

Their discussion includes:

• Dr. Lucas’ extensive pathology and research background and his journey to Mayo Clinic.
• His goals for expanding DLMP’s research activities and advancing innovation in diagnostics.
• How laboratory research has evolved over his career and how researchers can continue to make progress despite obstacles.
• The importance of having good mentors, collaborating with others, staying curious, and remaining persistent to achieve goals.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the widespread outbreaks of H5N1 bird flu and the new “FLiRT” variants of COVID-19.

Specific topics of discussion include:

• The current situation of avian flu activity across the world and throughout the United States, including outbreaks in poultry, U.S. dairy cows, and one recent human case.
• How this outbreak is different than previous ones, and the current public health risk.
• Resources for testing humans for avian flu.
• What we know about the new “FLiRT” variants of COVID-19 and how they might impact public health in the months ahead.

Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' augmented MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.

(00:31)
Can you tell us a little about yourself and your background — Beth?

(01:24)
Stephanie, what about you?

(01:42)
Dr. Jenkins, a little bit about yourself and your background, please?

(02:25)
Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?

(04:02)
What changes did you incorporate into the test?

(04:57)
Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?

(07:12)
Does including these genes guide patient care in a more valuable way?

(07:51)
What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?

(10:27)
Is having many options available in a one-stop shop important to help guide patient management?

(11:57)
Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care?